BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Beam Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$24.19+0.72 (+3.07%)
Close on Oct 19, 2026
- Market cap
- $2.52B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
109M of 103M shares
Institutional holders
277
59 new, 31 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 29 sales
Net sold $18.55M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roberts, Jr., Thomas G. | 8,239,123 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 7,499,930 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 5,228,529 | 5.20% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 5,122,475 | 5.02% | 13G (passive) | Mar 31, 2026 |
| FMR LLC | 13,766,518 | 13.60% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 12,750,369 | 12.60% | 13G (passive) amendment | Dec 31, 2025 |
| Catherine D. Wood | 12,467,189 | 12.29% | 13G (passive) amendment | Dec 31, 2025 |
| Spokes, Andrew J. M. | 10,282,210 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| ARK Investment Management LLC | 10,234,862 | 9.95% | 13G (passive) amendment | Jun 30, 2026 |
| Short Daniel S. | 10,141,856 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BEAM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,609,002 | 12.21% | $432.74M | +156,803 | 0.02% |
| Farallon Capital Management LLC | 10,236,396 | 9.91% | $351.31M | +101,700 | 1.62% |
| ARK Investment Management LLC | 10,234,862 | 9.91% | $351.26M | −1,898,571 | 2.28% |
| BlackRock, Inc. | 8,997,542 | 8.71% | $308.80M | +509,973 | 0.00% |
| State Street Corp | 5,827,122 | 5.64% | $199.99M | +127,857 | 0.01% |
| Vanguard Portfolio Management LLC | 4,921,259 | 4.76% | $168.90M | +350,462 | 0.01% |
| Vanguard Capital Management LLC | 4,599,437 | 4.45% | $157.85M | +222,063 | 0.00% |
| ARCH Venture Management, LLC | 4,540,132 | 4.40% | $155.77M | – | 14.16% |
| Sumitomo Mitsui Trust Holdings, Inc. | 3,455,043 | 3.35% | $118.58M | −370,542 | 0.07% |
| Nikko Asset Management Americas, Inc. | 3,455,043 | 3.35% | $118.54M | −370,542 | 1.53% |
| Price T Rowe Associates Inc /Md/ | 3,415,239 | 3.31% | $117.21K | +702,009 | 0.01% |
| Kynam Capital Management, LP | 2,840,792 | 2.75% | $97.50M | −841,393 | 5.39% |
| Geode Capital Management, LLC | 2,596,963 | 2.51% | $89.14M | +178,371 | 0.00% |
| Dimensional Fund Advisors LP | 2,225,844 | 2.15% | $76.40M | +71,269 | 0.01% |
| Morgan Stanley | 1,950,969 | 1.89% | $66.96M | +1,302,705 | 0.00% |
| Contrarius Group Holdings Ltd | 1,614,538 | 1.56% | $55.41M | +1,081,095 | 2.55% |
| UBS Asset Management Americas Inc | 1,551,781 | 1.50% | $53.26M | −101,933 | 0.01% |
| Two Sigma Investments, LP | 1,388,227 | 1.34% | $47.64M | +177,374 | 0.03% |
| Casdin Capital, LLC | 1,350,000 | 1.31% | $46.33M | – | 2.32% |
| Goldman Sachs Group Inc | 1,310,059 | 1.27% | $44.96M | +304,316 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 277 | 109M | 100.0% | 59 / 93 | 76 / 31 | 10M | 9M |
| Q1 2026 | 253 | 108M | 100.0% | 55 / 89 | 62 / 42 | 19M | 7M |
| Q4 2025 | 247 | 107M | 100.0% | 64 / 77 | 63 / 31 | 12M | 10M |
| Q3 2025 | 219 | 107M | 100.0% | 40 / 79 | 53 / 35 | 9M | 11M |
| Q2 2025 | 217 | 109M | 100.0% | 36 / 84 | 65 / 55 | 17M | 10M |
| Q1 2025 | 238 | 101M | 98.2% | 43 / 101 | 47 / 32 | 23M | 3M |
| Q4 2024 | 231 | 81M | 78.9% | 36 / 82 | 65 / 23 | 8M | 6M |
| Q3 2024 | 221 | 80M | 77.1% | 28 / 73 | 68 / 19 | 16M | 7M |
| Q2 2024 | 214 | 78M | 75.8% | 36 / 73 | 62 / 41 | 17M | 18M |
| Q1 2024 | 221 | 79M | 76.5% | 55 / 81 | 46 / 18 | 12M | 7M |
| Q4 2023 | 185 | 74M | 71.3% | 32 / 65 | 55 / 38 | 14M | 8M |
| Q3 2023 | 194 | 67M | 65.3% | 33 / 79 | 39 / 30 | 7M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BEAM | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 6,079,070 | 5.89% | $155.14M | 2.79% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 3,461,620 | 3.35% | $113.99M | 0.12% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,376,280 | 3.27% | $115.87M | 1.08% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,273,307 | 3.17% | $112.34M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,545,006 | 2.46% | $87.34M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,361,140 | 2.29% | $81.03M | 0.04% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 2,304,800 | 2.23% | $58.82M | 3.78% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,359,986 | 1.32% | $46.67M | 0.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,141,851 | 1.11% | $39.19M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,084,817 | 1.05% | $27.68M | 0.08% | Jul 31, 2026 |
| Fidelity Growth Company K6 Fund | 980,134 | 0.95% | $32.28M | 0.12% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 842,092 | 0.82% | $28.90M | 0.24% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 820,377 | 0.79% | $28.16M | 0.18% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 820,099 | 0.79% | $27.01M | 0.11% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 818,640 | 0.79% | $28.10M | 0.29% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John M. Evans | CEO, Director | 1,150,205 | 1.11% | Jul 1, 2026 |
| Giuseppe Ciaramella | President | 253,911 | 0.25% | Sep 25, 2026 |
| Amy Simon | Chief Medical Officer | 85,696 | 0.08% | Jul 29, 2026 |
| Bethany J. Cavanagh | SVP, Finance and Treasurer | 51,171 | 0.05% | Apr 6, 2026 |
| Christine Bellon | Chief Legal Officer | 109,711 | 0.11% | Apr 6, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 | 0.10% | Apr 2, 2026 |
| Graham K. Cooper | Director | 600 | 0.00% | Jun 5, 2026 |
| Christi Shaw | Director | – | – | Jun 5, 2026 |
| Mark Fishman | Director | 17,007 | 0.02% | Jun 5, 2026 |
| Kathleen E. Walsh | Director | – | – | Jun 5, 2026 |
| John Maraganore | Director | – | – | Jun 5, 2026 |
| Chirfi Guindo | Director | – | – | Jun 5, 2026 |
| Carole Ho | Director | – | – | Jun 6, 2025 |
| Llc Fmr | 10% owner | 1,695,828 | 1.64% | Jun 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Giuseppe Ciaramella President | Sep 24, 2026 | Gift | −123,407 | – | – | 130,504 |
| Amy Simon Chief Medical Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −16,667 | $25.74 | $429.01K | 85,696 |
| Amy Simon Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −373 | $34.73 | $12.95K | 102,363 |
| John M. Evans CEO, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −1,900 | $34.84 | $66.20K | 1,047,205 |
| John M. Evans CEO, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −23,100 | $34.26 | $791.41K | 1,049,105 |
| John M. Evans CEO, Director | Jun 30, 2026 | Option exercise | +25,000 | $1.03 | $25.75K | 1,072,205 |
| John M. Evans CEO, Director | Jun 29, 2026 | Option exercise | +18,663 | $0.67 | $12.50K | 1,065,868 |
| John M. Evans CEO, Director | Jun 29, 2026 | Option exercise | +6,337 | $1.03 | $6.53K | 1,072,205 |
| John M. Evans CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −13,421 | $35.13 | $471.48K | 1,058,784 |
| John M. Evans CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −11,579 | $35.91 | $415.80K | 1,047,205 |
| Llc Fmr 10% owner | Jun 26, 2026 | Sale | −251,488 | $35.26 | $8.87M | 854,583 |
| Llc Fmr 10% owner | Jun 25, 2026 | Sale | −33,372 | $35.12 | $1.17M | 1,106,071 |
| Giuseppe Ciaramella President | Jun 17, 2026 | Option exercise | +29,000 | $1.03 | $29.87K | 253,911 |
| Giuseppe Ciaramella President | Jun 17, 2026 | Option exercise | +6,505 | $0.67 | $4.36K | 224,911 |
| John M. Evans CEO, Director | Apr 1, 2026 | Sale(10b5-1 plan) | −30,078 | $24.58 | $739.32K | 1,047,205 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Apr 1, 2026 | Sale(10b5-1 plan) | −3,242 | $24.58 | $79.69K | 51,171 |
| Christine Bellon Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −5,956 | $24.58 | $146.40K | 109,711 |
| Giuseppe Ciaramella President | Apr 1, 2026 | Sale(10b5-1 plan) | −11,810 | $24.58 | $290.29K | 218,406 |
| Amy Simon Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −6,700 | $24.58 | $164.69K | 102,735 |
| Giuseppe Ciaramella President | Mar 31, 2026 | Award | +40,000 | – | – | 230,216 |
| Sravan Kumar Emany Chief Financial Officer | Mar 31, 2026 | Award | +31,750 | – | – | 105,456 |
| Christine Bellon Chief Legal Officer | Mar 31, 2026 | Award | +20,000 | – | – | 115,667 |
| Amy Simon Chief Medical Officer | Mar 31, 2026 | Award | +31,750 | – | – | 109,114 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Mar 31, 2026 | Award | +20,000 | – | – | 54,813 |
| John M. Evans CEO, Director | Mar 31, 2026 | Award | +90,000 | – | – | 1,076,667 |
| John M. Evans CEO, Director | Mar 31, 2026 | Sale(10b5-1 plan) | −25,000 | $22.76 | $569.00K | 986,667 |
| John M. Evans CEO, Director | Mar 31, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Mar 30, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Mar 30, 2026 | Sale(10b5-1 plan) | −25,000 | $22.37 | $559.25K | 986,667 |
| Giuseppe Ciaramella President | Feb 24, 2026 | Sale(10b5-1 plan) | −35,000 | $32.00 | $1.12M | 190,216 |
| Giuseppe Ciaramella President | Feb 24, 2026 | Option exercise | +35,000 | $17.00 | $595.00K | 225,216 |
| John M. Evans CEO, Director | Jan 30, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Jan 30, 2026 | Sale(10b5-1 plan) | −22,094 | $28.27 | $624.60K | 989,573 |
| John M. Evans CEO, Director | Jan 30, 2026 | Sale(10b5-1 plan) | −2,906 | $29.00 | $84.27K | 986,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Sale(10b5-1 plan) | −8,667 | $29.74 | $257.76K | 986,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Sale(10b5-1 plan) | −16,333 | $29.19 | $476.76K | 995,334 |
| John M. Evans CEO, Director | Jan 29, 2026 | Option exercise | +5,664 | $0.67 | $3.79K | 1,011,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Option exercise | +19,336 | $0.67 | $12.96K | 1,006,003 |
| Christine Bellon Chief Legal Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −1,371 | $34.00 | $46.61K | 95,667 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Jan 22, 2026 | Sale(10b5-1 plan) | −6,198 | $35.00 | $216.93K | 34,813 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Jan 20, 2026 | Sale(10b5-1 plan) | −3,034 | $30.12 | $91.38K | 41,011 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −559 | $35.40 | $19.79K | 97,038 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −2,111 | $33.62 | $70.97K | 113,556 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −15,959 | $34.72 | $554.10K | 97,597 |
| Christine Bellon Chief Legal Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −1,254 | $27.10 | $33.98K | 115,667 |
| Amy Simon Chief Medical Officer | Dec 31, 2025 | Award | +12,500 | – | – | 77,364 |
| Sravan Kumar Emany Chief Financial Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −6,294 | $27.10 | $170.57K | 73,706 |
| Llc Fmr 10% owner | Oct 27, 2025 | Sale | −459 | $26.68 | $12.25K | 14 |
| Llc Fmr 10% owner | Oct 6, 2025 | Gift | −1,232,434 | – | – | 841,231 |
| John M. Evans CEO, Director | Oct 2, 2025 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Oct 2, 2025 | Sale(10b5-1 plan) | −25,000 | $24.63 | $615.75K | 986,667 |
| John M. Evans CEO, Director | Oct 1, 2025 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −25,000 | $24.51 | $612.75K | 986,667 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Oct 1, 2025 | Sale(10b5-1 plan) | −467 | $24.53 | $11.46K | 44,045 |
| Christine Bellon Chief Legal Officer | Oct 1, 2025 | Sale(10b5-1 plan) | −373 | $24.53 | $9.15K | 116,921 |
| Llc Fmr 10% owner | Jul 30, 2025 | Sale | −48,374 | $20.50 | $991.67K | 2,073,665 |
| Amy Simon Chief Medical Officer | Jul 3, 2025 | Sale(10b5-1 plan) | −876 | $20.12 | $17.63K | 64,864 |
| Amy Simon Chief Medical Officer | Jul 1, 2025 | Sale(10b5-1 plan) | −374 | $16.94 | $6.34K | 65,740 |
| Amy Simon Chief Medical Officer | Apr 2, 2025 | Sale(10b5-1 plan) | −20,997 | $17.73 | $372.28K | 65,742 |
| Christine Bellon Chief Legal Officer | Apr 1, 2025 | Sale(10b5-1 plan) | −5,674 | $18.35 | $104.12K | 117,294 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| M. Evans John Officer, Director | Oct 16, 2026 | 25,000 | $599.60K | Oct 16, 2026 | Stock Option Exercise |
| M. Evans John Officer, Director | Oct 15, 2026 | 25,000 | $589.15K | Oct 15, 2026 | Stock Option Exercise |
| Simon Amy Officer | Jul 27, 2026 | 16,677 | $429.29K | Jul 27, 2026 | Restricted Stock |
| M. Evans John Officer, Director | Jun 30, 2026 | 25,000 | $857.69K | Jun 30, 2026 | Stock Option Exercise |
| M. Evans John Officer, Director | Jun 29, 2026 | 25,000 | $887.35K | Jun 29, 2026 | Stock Option Exercise |
| Ho Carole Director | Apr 14, 2026 | 87,784 | $2.70M | Apr 14, 2026 | Stock Option Exercise |
| M. Evans John Officer, Director | Mar 31, 2026 | 25,000 | $569.09K | Mar 31, 2026 | Stock Option Exercise |
| Simon Amy Officer | Mar 31, 2026 | 20,000 | $438.00K | Apr 2, 2026 | Restricted Stock Vesting |
| M. Evans John Officer, Director | Mar 31, 2026 | 66,874 | $1.46M | Apr 2, 2026 | Restricted Stock Vesting |
| Ciaramella Giuseppe Officer | Mar 31, 2026 | 26,250 | $574.88K | Apr 2, 2026 | Restricted Stock Vesting |
| Bellon Christine Officer | Mar 31, 2026 | 20,000 | $438.00K | Apr 2, 2026 | Restricted Stock Vesting |
| M. Evans John Officer, Director | Mar 30, 2026 | 25,000 | $559.23K | Mar 30, 2026 | Stock Option Exercise |
| Ciaramella Giuseppe Officer | Feb 24, 2026 | 35,000 | $1.12M | Feb 24, 2026 | Stock Option Exercise |
| M. Evans John Officer, Director | Jan 30, 2026 | 25,000 | $708.95K | Jan 30, 2026 | Stock Option Exercise |
| M. Evans John Officer, Director | Jan 29, 2026 | 25,000 | $734.58K | Jan 29, 2026 | Stock Option Exercise |